Detalhe da pesquisa
1.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966830
2.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(1): 44-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786121
3.
Baseline risk factors associated with immune related adverse events and atezolizumab.
Front Oncol
; 13: 1138305, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925916
4.
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Genome Med
; 15(1): 45, 2023 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344884
5.
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
J Clin Pharmacol
; 62(11): 1393-1402, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576521
6.
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.
Nat Commun
; 12(1): 3355, 2021 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099659
7.
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Clin Pharmacol Drug Dev
; 10(10): 1142-1155, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33788415
8.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
J Clin Oncol
; 39(17): 1842-1855, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891472